CA2321113A1 - Anticorps monoclonaux anti-inositolphosphoglyanne - Google Patents

Anticorps monoclonaux anti-inositolphosphoglyanne Download PDF

Info

Publication number
CA2321113A1
CA2321113A1 CA002321113A CA2321113A CA2321113A1 CA 2321113 A1 CA2321113 A1 CA 2321113A1 CA 002321113 A CA002321113 A CA 002321113A CA 2321113 A CA2321113 A CA 2321113A CA 2321113 A1 CA2321113 A1 CA 2321113A1
Authority
CA
Canada
Prior art keywords
ipg
antibody
ipgs
type
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321113A
Other languages
English (en)
Inventor
Thomas William Rademacher
Phillip Williams
Jesus Prieto
Isabel Varela Nieto
Jose Mato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rodaris Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805739.1A external-priority patent/GB9805739D0/en
Priority claimed from GBGB9811000.0A external-priority patent/GB9811000D0/en
Application filed by Individual filed Critical Individual
Publication of CA2321113A1 publication Critical patent/CA2321113A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps anti-IPG, et plus particulièrement des anticorps monoclonaux produits par les lignées cellulaires hybridomes 2F7, 2D1, et 5H6. L'invention concerne également l'utilisation des anticorps susmentionnés et d'autres anticorps similaires, afin de diagnostiquer et de traiter la prééclampsie ou les diabètes, en particulier les diabètes du type I. L'invention concerne enfin une méthode de production desdits anticorps anti-IPG, par immunisation d'un animal avec un IPG non conjugué à un excipient immunogène.
CA002321113A 1998-03-18 1999-03-18 Anticorps monoclonaux anti-inositolphosphoglyanne Abandoned CA2321113A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9805739.1A GB9805739D0 (fr) 1998-03-18 1998-03-18
GB9805739.1 1998-03-18
GBGB9811000.0A GB9811000D0 (fr) 1998-05-21 1998-05-21
GB9811000.0 1998-05-21
PCT/GB1999/000844 WO1999047565A1 (fr) 1998-03-18 1999-03-18 Anticorps monoclonaux anti-inositolphosphoglyanne

Publications (1)

Publication Number Publication Date
CA2321113A1 true CA2321113A1 (fr) 1999-09-23

Family

ID=26313300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321113A Abandoned CA2321113A1 (fr) 1998-03-18 1999-03-18 Anticorps monoclonaux anti-inositolphosphoglyanne

Country Status (5)

Country Link
EP (1) EP1062246A1 (fr)
JP (1) JP2002506631A (fr)
AU (1) AU748080B2 (fr)
CA (1) CA2321113A1 (fr)
WO (1) WO1999047565A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039285A2 (fr) * 1998-12-24 2000-07-06 University College London Proteines d phospholipase specifiques du glycosyl phosphatidy linositol et leurs utilisations
WO2001086292A2 (fr) * 2000-05-12 2001-11-15 Rodaris Pharmaceutical Limited Dosages biologiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
GB9618929D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate glycogen metabolism
GB9618930D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate lipogenic activity

Also Published As

Publication number Publication date
JP2002506631A (ja) 2002-03-05
WO1999047565A1 (fr) 1999-09-23
AU2946799A (en) 1999-10-11
EP1062246A1 (fr) 2000-12-27
AU748080B2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
Rothenberger et al. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium
DE69936780T2 (de) Antikörper gegen eine lar-phosphatase untereinheit
JP3758686B2 (ja) Ｃペプチド特異的アッセイ法
Lee et al. The murine lymphocyte receptor for IgE. IV. The mechanism of ligand-specific receptor upregulation on B cells.
DE60025008T2 (de) Bestimmung von adrenomedullin-bindenden proteinen
EA029271B1 (ru) Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения
JPH08511940A (ja) αＰＤＧＦ受容体に対するモノクローナル抗体およびその使用
US9783600B2 (en) Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
Merlie et al. Acetylcholine receptor degradation in adult rat diaphragms in organ culture and the effect of anti-acetylcholine receptor antibodies.
KR20080106157A (ko) Ｆａｓ 결합 항체
JP2007536212A (ja) レプチンアンタゴニストおよびレプチン定量測定方法
JPH09507578A (ja) インスリン受容体チロシンキナーゼインヒビターに対するアンタゴニスト
JPWO2008018472A1 (ja) 新規モノクローナル抗体およびその用途
JPH09507754A (ja) 哺乳類悪性細胞の選択的メチオニン飢餓方法
JP2001519894A (ja) リソソーム蓄積症の早期検出法
EP0443599B1 (fr) Méthode pour la détection des des antigènes associés aux tumeurs
US8038997B2 (en) Anti-marinobufagenin antibodies and methods for their use
AU748080B2 (en) Anti-inositolphosphoglycan monoclonal antibodies
US7595047B2 (en) Compositions and methods for promoting or inhibiting angiogenesis
Yamamoto et al. Immunohistochemistry for anti-diabetes drug, alogliptin using a newly prepared monoclonal antibody: Its precise localization in rat small intestine
US20040192586A1 (en) Materials and methods relating to anti-inositolphosphoglycan antibodies
US5939269A (en) Antagonists to insulin receptor tyrosine kinase inhibitor
US6777394B1 (en) Methods and compositions for regulating imidazoline receptors
JP2792651B2 (ja) ヒト膵臓癌に対するモノクローナル抗体
JPH10508831A (ja) ビタミンｂ１２／トランスコバラミンｉｉレセプターおよび結合部位に対する抗レセプターおよび増殖阻止剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead